DM is reaching epidemic proportions worldwide, and the contributions of medications to the development of hyperglycemia and other metabolic derangements is receiving more attention. Pharmacists are in a unique position to counsel and encourage appropriate self-monitoring in patients receiving certain drugs, such as antipsychotics, that can contribute to the development of weight gain, hyperglycemia, and dyslipidemia. Pharmacists can serve as a catalyst for patients receiving antipsychotics to communicate adverse events to other health care providers and seek therapeutic substitutions, counseling, and/or treatment if adverse events result from treatment. As a population, people with schizophrenia often have poor access to care and lower levels of psychosocial support; thus, the pharmacist's recognition and intervention in this population have the potential to improve quality of care.